


## Continuous Renal Replacement Therapy Market to Hit \$2.6 Billion by 2031 Amid 13.3 Million Global AKI Cases

PORTLAND, OR, UNITED STATES, October 30, 2024 /EINPresswire.com/ --The global <u>Continuous Renal</u> <u>Replacement Therapy (CRRT) Market</u> is experiencing notable growth, driven by an increasing prevalence of acute kidney injury (AKI) and advancements in renal care technology. Valued at \$1.3 billion in 2021, the market is expected to reach \$2.6 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.7% from 2022 to 2031. CRRT is a slow, continuous extracorporeal blood purification



Continuous Renal Replacement Therapy Market size, share, demand, growth and analysis

process that gently removes excess fluids and toxins over extended periods, catering especially to critical patients with renal complications.

000 0 00000 0000 00 0000 000000: <u>https://www.alliedmarketresearch.com/request-</u> sample/A11923

## Key Growth Drivers

• Rise in Acute Kidney Injury Cases: Approximately 13.3 million cases globally (2020), as reported by the International Society of Nephrology.

• Sepsis Incidence and Rising Demand for CRRT: Increased cases of sepsis fuel the adoption of CRRT, a preferred method for managing kidney-related complications in critical care.

• Technological Advancements in Pediatric CRRT: Medtronic's Carpediem Cardio-Renal machine, launched in 2020, is tailored for pediatric patients (weighing 2.5–10 kg), marking advancements in CRRT for young patients.

## Market Segmentation Overview

- By Product:
- Dialysates and Replacement Fluids: Leading segment in 2021 due to increased AKI cases.
- Disposables: Expected to grow significantly, supported by rising kidney disorder rates and

aging populations.

• By Modality:

• Continuous Venovenous Hemofiltration (CVVH): The most popular modality, preferred for its capability to remove large fluid volumes smoothly, without causing hypotension.

• Continuous Venovenous Hemodiafiltration (CVVHDF): Gaining traction for its efficacy in treating acute renal failure, particularly beneficial for elderly patients.

• By Age Group:

• Adults: Dominates the market, driven by regulatory approvals and innovations for adult CRRT.

• Pediatrics: Anticipated growth due to increasing acute kidney disorders in children and product development in pediatric CRRT.

• By Region:

• Asia-Pacific: Holds the largest share, attributed to R&D investments and regional expansion by CRRT providers.

• North America: Expected to grow due to high healthcare expenditures and rising prevalence of kidney disease.

Key Challenges and Opportunities

• Cost Constraints: CRRT costs range from \$389–\$600 per day, creating accessibility issues in developing regions.

• Limited Awareness in Emerging Markets: Countries like Brazil and South Africa face CRRT adoption challenges due to inadequate funding and healthcare infrastructure.

• Regulatory Approvals: Increasing government initiatives and regulatory support are creating opportunities for market expansion.

Leading Market Players

Some prominent companies in the CRRT market include:

- Medtronic plc
- Baxter International Inc.
- Fresenius Medical Care AG & Co. KGaA
- Asahi Kasei Corporation
- B. Braun Melsungen AG

Key Takeaways

• The <u>Continuous Renal Replacement Therapy market</u> is witnessing rapid growth due to rising AKI cases and advancements in renal replacement technologies.

• Pediatric-focused CRRT devices are expected to capture a significant market share.

• The Asia-Pacific region remains the largest market, with North America projected to grow substantially due to unmet medical needs and increased healthcare spending.

This growth highlights a crucial market for innovations in renal care and presents opportunities for strategic expansions in emerging regions.

000000 000000 000000: <u>https://www.alliedmarketresearch.com/purchase-enquiry/A11923</u>

David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social media: Facebook X

This press release can be viewed online at: https://www.einpresswire.com/article/756183996

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.